B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)
In patients with immune-mеdiated (autoimmune) rheumatic diseases (IMIRD), there are a number of factors (advanced age, uncontrolled inflammation, initially irreversible damage to internal organs, comorbid pathology, genetic and other factors) that can potentially lead to an increase in “sensitivity”...
Saved in:
Main Authors: | E. L. Nasonov, A. S. Avdeeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2021-09-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/3054 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity
by: E. L. Nasonov, et al.
Published: (2020-09-01) -
Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19
by: E. L. Nasonov, et al.
Published: (2022-05-01) -
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia
by: E. L. Nasonov, et al.
Published: (2021-07-01) -
Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects
by: E. L. Nasonov
Published: (2024-03-01) -
Rituximab for rheumatic diseases in children: Results of a retrospective study of the safety of therapy
by: M. I. Kaleda, et al.
Published: (2021-05-01)